Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Goodwill & Intangibles (2023 - 2025)

Historic Goodwill & Intangibles for Iovance Biotherapeutics (IOVA) over the last 6 years, with Q3 2025 value amounting to $335.3 million.

  • Iovance Biotherapeutics' Goodwill & Intangibles changed N/A to $335.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.3 million, marking a year-over-year change of. This contributed to the annual value of $313.1 million for FY2024, which is 3085.21% up from last year.
  • Iovance Biotherapeutics' Goodwill & Intangibles amounted to $335.3 million in Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Goodwill & Intangibles peaked at $341.4 million during Q2 2025, and registered a low of $223.6 million during Q3 2023.
  • For the 3-year period, Iovance Biotherapeutics' Goodwill & Intangibles averaged around $288.1 million, with its median value being $303.7 million (2024).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Goodwill & Intangibles surged by 3085.21% in 2024, and later skyrocketed by 957.55% in 2025.
  • Iovance Biotherapeutics' Goodwill & Intangibles (Quarter) stood at $239.3 million in 2023, then surged by 30.85% to $313.1 million in 2024, then grew by 7.1% to $335.3 million in 2025.
  • Its Goodwill & Intangibles stands at $335.3 million for Q3 2025, versus $341.4 million for Q2 2025 and $322.5 million for Q1 2025.